Priority Research Papers:
The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization
Metrics: PDF 1580 views | HTML 2173 views | ?
Heng Zhou1,2,3,4,5, Sabrina Forveille1,2,3,4, Allan Sauvat1,2,3,4, Valentina Sica1,2,3,4,5, Valentina Izzo1,2,3,4, Sylvère Durand1,2,3,4, Kevin Müller1,2,3,4,5, Peng Liu1,2,3,4,5, Laurence Zitvogel5,6,7, Øystein Rekdal9,10, Oliver Kepp1,2,3,4 and Guido Kroemer1,2,3,4,11,12
1 Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France
2 Equipe 11 Labellisée Ligue Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U 1138, Paris, France
3 Université Paris Descartes, Sorbonne Paris Cité, Paris, France
4 Université Pierre et Marie Curie, Paris, France
5 University of Paris Sud XI, Kremlin Bicêtre, France
6 Department of Immuno-Oncology, Institut de Cancérologie Gustave Roussy Cancer Campus, Villejuif, France
7 Institut National de la Santé et de la Recherche Medicale (INSERM), U1015, Villejuif, France
8 Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France
9 Lytix Biopharma, Oslo, Norway
10 University of Tromsø, Institute of Medical Biology, Tromsø, Norway
11 Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
12 Karolinska Institute, Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, Sweden
Oliver Kepp , email:
Guido Kroemer, email:
Keywords: LTX-315, necrosis, mitochondrial membrane permeabilization, cancer, mitophagy
Received: July 31, 2015 Accepted: August 26, 2015 Published: September 10, 2015
LTX-315 has been developed as an amphipathic cationic peptide that kills cancer cells. Here, we investigated the putative involvement of mitochondria in the cytotoxic action of LTX-315. Subcellular fractionation of LTX-315-treated cells, followed by mass spectrometric quantification, revealed that the agent was enriched in mitochondria. LTX-315 caused an immediate arrest of mitochondrial respiration without any major uncoupling effect. Accordingly, LTX-315 disrupted the mitochondrial network, dissipated the mitochondrial inner transmembrane potential, and caused the release of mitochondrial intermembrane proteins into the cytosol. LTX-315 was relatively inefficient in stimulating mitophagy. Cells lacking the two pro-apoptotic multidomain proteins from the BCL-2 family, BAX and BAK, were less susceptible to LTX-315-mediated killing. Moreover, cells engineered to lose their mitochondria (by transfection with Parkin combined with treatment with a protonophore causing mitophagy) were relatively resistant against LTX-315, underscoring the importance of this organelle for LTX-315-mediated cytotoxicity. Altogether, these results support the notion that LTX-315 kills cancer cells by virtue of its capacity to permeabilize mitochondrial membranes.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.